The active arms showed a trend toward improvement over placebo () 33% complete healing after 30 days in the active group versus 19% in the placebo group
More than doubled the incidence of complete healing (), increased the mean closure rate 80% (), and decreased the median time to 100% closure by 40% ().
Proportion of patients with wound closure increased in TGF-β2 at doses of 0.05 μg/cm2 () and 0.5 μg/cm2 () and group with standardized care treatment (). In total, the mean time to complete wound closure was shorter in TGF-β 0.5 μg/cm2 () compared with the placebo group